非高密度脂蛋白胆固醇与载脂蛋白B在心血管疾病风险评估中的比较

被引：13

作者：

胡璐

赵水平

机构：

[1] 中南大学湘雅二医院心血管内科

来源：

中国动脉硬化杂志 | 2012年 / 08期

关键词：

心血管疾病; 非高密度脂蛋白胆固醇; 载脂蛋白B; 低密度脂蛋白胆固醇;

D O I：

暂无

中图分类号：

R54 [心脏、血管（循环系）疾病]; R589.2 [脂肪代谢障碍];

学科分类号：

摘要：

非高密度脂蛋白胆固醇水平反映致动脉粥样硬化胆固醇总量,载脂蛋白B浓度反应致动脉粥样硬化颗粒总数。近期研究发现非高密度脂蛋白胆固醇和载脂蛋白B的心血管疾病风险预测价值优于传统指标低密度脂蛋白胆固醇。文章就这两个指标的心血管风险评估效能及临床操作性能做一综述。

引用

页码：755 / 759

页数：5

共 13 条

[1] 非高密度脂蛋白胆固醇对冠状动脉病变的影响 [J].

许海燕 ;

乔树宾 ;

张家芬 ;

徐波 ;

顼志敏 ;

杨跃进 ;

董秋婷 .

中国动脉硬化杂志, 2010, 18 (05) :409-411

[2] 载脂蛋白A1和B的参考值及临床意义 [J].

庄一义 .

中国动脉硬化杂志, 2006, (03) :263-266

[3]

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies[J] . Dick C Chan,Gerald F Watts.Expert Opinion on Pharmacotherapy . 2011 (1)

[4] Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes [J].

Taskinen, M. -R. ;

Barter, P. J. ;

Ehnholm, C. ;

Sullivan, D. R. ;

Mann, K. ;

Simes, J. ;

Best, J. D. ;

Hamwood, S. ;

Keech, A. C. .

DIABETOLOGIA, 2010, 53 (09) :1846-1855

[5]

Small, dense LDL cholesterol and apolipoprotein B: Relationship with serum lipids and LDL size[J] . Jelena Vekic,Aleksandra Zeljkovic,Zorana Jelic-Ivanovic,Vesna Spasojevic-Kalimanovska,Natasa Bogavac-Stanojevic,Lidija Memon,Slavica Spasic.Atherosclerosis . 2009 (2)

[6]

Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines[J] . Amit Sachdeva,Christopher P. Cannon,Prakash C. Deedwania,Kenneth A. LaBresh,Sidney C. Smith,David Dai,Adrian Hernandez,Gregg C. Fonarow.American Heart Journal . 2009 (1)

[7]

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations[J] . Jacques Genest,Ruth McPherson,Jiri Frohlich,Todd Anderson,Norm Campbell,André Carpentier,Patrick Couture,Robert Dufour,George Fodor,Gordon A. Francis,Steven Grover,Milan Gupta,Robert A. Hegele,David C. Lau,Lawrence Leiter,Gary F. Lewis,Eva Lonn,G.B. John Mancini,Dominic Ng,Glen J. Pearson,Allan Sniderman,James A

[8]

Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice[J] . Allan D. Sniderman.Journal of Clinical Lipidology . 2008 (1)

[9]

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study[J] . Matthew J McQueen,Steven Hawken,Xingyu Wang,Stephanie Ounpuu,Allan Sniderman,Jeffrey Probstfield,Krisela Steyn,John E Sanderson,Mohammad Hasani,Emilia Volkova,Khawar Kazmi,Salim Yusuf.The Lancet . 2008 (9634)

[10]

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment[J] . John J.P. Kastelein,Wim A. van der Steeg,Ingar Holme,Michael Gaffney,Nilo B. Cater,Philip Barter,Prakash Deedwania,Anders G. Olsson,S Matthijs Boekholdt,David A. Demicco,Michael Szarek,John C. LaRosa,Terje R. Pedersen,Scott M. Grundy.Circulation . 2008 (23)

← 1 2 →